General Info

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference. The company develops RNAi-based compounds and drug delivery technologies that together provide therapeutic options for patients. Over the past decade, it has developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which are applied to a wide range of RNAi technologies and delivery approaches. MDRNA also invests in new technologies that are expected to lead to safer and more effective RNAi-based therapeutics while aggressively building upon their broad intellectual property estate. The company also has experience in complex clinical trials and regulatory filings, which is critical to accelerated development. MDRNA maintains facilities in Bothell, Wash.